Sector News

Mallinckrodt buys Ikaria for $2.3bn

March 6, 2015
Life sciences
Dublin, Ireland-based speciality biopharma Mallinckrodt is extending its hospital-based offering with a $2.3-billion purchase of US privately-held critical care group Ikaria.
 
A Mallinckrodt subsidiary will acquire the company from a Madison Dearborn-led investor group, with the transaction is expected to close early in the second quarter assuming closing conditions are satisfied.
 
The firm says the deal will further accelerate growth in its Specialty Brands segment, broaden its hospital presence, and diversify its portfolio with “high-value, high-margin critical care products”.
 
The move is expected to add at least $150 million in net sales and be accretive to Mallinckrodt’s fiscal year 2015 adjusted diluted earnings per share by at least $0.25 per share.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.